

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 73, ISSUE 3, PAGES 475–744

FROM THE EDITOR'S DESK

From the Editor's Desk...

P. Burra, F. Tacke, V. Ratziu, S. Zeuzem, B. Sangro and P. Angeli 475

EDITORIALS

EASL Recognition Award Recipient 2020: Prof. Roger Williams

R. Jalan 479

EASL Recognition Award Recipient 2020: Prof. Patrick Marcellin

G. Dusheiko 482

EASL Recognition Awardee 2020: Prof. Giovanna Fattovich

A. Craxi 484

EASL Recognition Award Recipient 2020: Prof. James L. Boyer

M. Trauner 487

Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination

J.V. Lazarus, C.A. Picchio, S. Nayagam, S. Ratzan and M. Thursz 490

The burden of hepatitis D – defogging the epidemiological horizon

H. Wedemeyer 493

Interferon revisited: Peering behind the lines of antiviral defense

A. Virzi, A.A. Roca Suarez and J. Lupberger 496

UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice

J.K. Dyson and D.E.J. Jones 499

Maternal obesity: A severe risk factor in hepatocarcinogenesis?

S. Colnot and A. Lechel 502

RESEARCH ARTICLES

NAFLD and Alcohol-Related Liver Diseases

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort

Q.M. Anstee, R. Darlay, S. Cockell, M. Meroni, O. Govaere, D. Tiniakos, A.D. Burt, P. Bedossa, J. Palmer, Y.-L. Liu, G.P. Aithal, M. Allison, H. Yki-Järvinen, M. Vacca, J.-F. Dufour, P. Invernizzi, D. Prati, M. Ekstedt, S. Kechagias, S. Francque, S. Petta, E. Bugianesi, K. Clement, V. Ratziu, J.M. Schattenberg, L. Valenti, C.P. Day, H.J. Cordell and A.K. Daly, on behalf of the EPoS Consortium Investigators 505

Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes

M. Sarkar, J. Grab, J.L. Dodge, E.P. Gunderson, J. Rubin, R.A. Irani, M. Cedars and N. Terrault 516

Viral Hepatitis

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis

A.J. Stockdale, B. Kreuels, M.Y.R. Henrion, E. Giorgi, I. Kyomuhangi, C. de Martel, Y. Hutin and A.M. Geretti 523

Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies

D. Alfaiate, S. Clément, D. Gomes, N. Goossens and F. Negro 533

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort

E.C. Verna, G. Morelli, N.A. Terrault, A.S. Lok, J.K. Lim, A.M. Di Bisceglie, S. Zeuzem, C.S. Landis, P. Kwo, M. Hassan, M.P. Manns, M. Vainorius, L. Akushevich, D.R. Nelson, M.W. Fried and K.R. Reddy 540

C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle

V. Kinast, A. Plociennikowska, Anggakusuma, T. Bracht, D. Todt, R.J.P. Brown, T. Boldanova, Y. Zhang, Y. Brüggemann, M. Friesland, M. Engelmann, G. Vieyres, R. Broering, F.W.R. Vondran, M.H. Heim, B. Sitek, R. Bartenschlager, T. Pietschmann and E. Steinmann 549

DILI, Autoimmune, Cholestatic and Genetic Diseases

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

C. Corpechot, O. Chazouillères, P. Belnou, A.J. Montano-Loza, A. Mason, M. Ebadi, D. Eurich, S. Chopra, D. Jacob, C. Schramm, M. Sterneck, T. Bruns, P. Reuken, F. Rauchfuss, D. Roccarina, D. Thorburn, A. Gerussi, P. Trivedi, G. Hirschfield, P. McDowell, F. Nevens, O. Boillot, A. Bosch, E. Giostra, F. Conti, R. Poupon, A. Parés, A. Reig, M.F. Donato, F. Malinverno, A. Floreani, F.P. Russo, N. Cazzagon, X. Verhelst, J. Goet, M. Harms, H. van Buuren, B. Hansen, F. Carrat and J. Dumortier, on behalf of the Global PBC Study Group 559

COVID-19: Abnormal liver function tests

Q. Cai, D. Huang, H. Yu, Z. Zhu, Z. Xia, Y. Su, Z. Li, G. Zhou, J. Gou, J. Qu, Y. Sun, Y. Liu, Q. He, J. Chen, L. Liu and L. Xu 566

Cirrhosis and Liver Failure

Changes in frailty are associated with waitlist mortality in patients with cirrhosis

J.C. Lai, J.L. Dodge, M.R. Kappus, M.A. Dunn, M.L. Volk, A. Duarte-Rojo, D.R. Ganger, R.S. Rahimi, C.E. McCulloch, C.E. Haugen, M. McAdams-DeMarco, D.P. Ladner, D.L. Segev and E.C. Verna, from the Multi-Center Functional Assessment in Liver Transplantation (FrALT) Study 575

Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF- α treatment

T. Balzano, S. Dadsetan, J. Forteza, A. Cabrera-Pastor, L. Taoro-Gonzalez, M. Malaguamera, S. Gil-Perotin, L. Cubas-Núñez, B. Casanova, A. Castro-Quintas, A. Ponce-Mora, Y.M. Arenas, P. Leone, S. Erceg, M. Llansola and V. Felipo 582

Hepatic and Biliary Cancer

Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis

A. Sangiovanni, E. Alimenti, R. Gattai, R. Filomia, E. Parente, L. Valenti, L. Marzi, G. Pellegatta, G. Borgia, M. Gambato, N. Terreni, I. Serio, L. Belli, F. Oliveri, S. Maimone, M. Brunacci, R. D'Ambrosio, L.V. Forzenigo, F.P. Russo, M. Rumi, M. Barone, A.L. Fracanzani, G. Raimondo, E.G. Giannini, M.R. Brunetto, E. Villa, E. Biganzoli, M. Colombo and P. Lampertico 593

Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p

Y. Sun, Q. Wang, Y. Zhang, M. Geng, Y. Wei, Y. Liu, S. Liu, R.B. Petersen, J. Yue, K. Huang and L. Zheng 603

Experimental and Translational Hepatology

MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis

X. Wu, K.L. Poulsen, C. Sanz-Garcia, E. Huang, M.R. McMullen, S. Roychowdhury, S. Dasarathy and L.E. Nagy 616

Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals

M. Hassan, S. Moghadamrad, M. Sorribas, S.G. Muntet, P. Kellmann, C. Trentesaux, M. Fraudeau, P. Nanni, W. Wolski, I. Keller, S. Hapfelmeier, N.F. Shroyer, R. Wiest, B. Romagnolo and A. De Gottardi 628

Human liver CD8⁺ MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in response to IL-15
M.-S. Rha, J.W. Han, J.H. Kim, J.-Y. Koh, H.J. Park, S.I. Kim, M.S. Kim, J.G. Lee, H.W. Lee, D.H. Lee, W. Kim, J.Y. Park, D.J. Joo, S.-H. Park and E.-C. Shin 640

REVIEWS

Variants in *ABCB4* (MDR3) across the spectrum of cholestatic liver diseases in adults

A.F. Stättermayer, E. Halilbasic, F. Wrba, P. Ferenci and M. Trauner 651

Epitranscriptomics in liver disease: Basic concepts and therapeutic potential

Z. Zhao, J. Meng, R. Su, J. Zhang, J. Chen, X. Ma and Q. Xia 664

Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

O. Glass, C. Filozof, M. Noureddin, M. Berner-Hansen, E. Schabel, S.O. Omokaro, J.M. Schattenberg, K. Barradas, V. Miller, S. Francque and M.F. Abdelmalek, for the Liver Forum Standard of Care Working Group 680

SPECIAL SECTION

Hepatology Snapshot

Hepatitis B virus – recent therapeutic advances and challenges to cure

K. Mouzannar and T.J. Liang 694

LETTERS TO THE EDITOR

Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study

M. Cornberg, S. Pischke, T. Müller, P. Behrendt, F. Piecha, J. Benckert, D. Todt, E. Steinmann, A. Papkalla, M. von Karpowitz, A. Koch, A. Lohse, S. Hardtke, M.P. Manns and H. Wedemeyer 696

Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis

A. Hamon, C. Piquet-Pellorce, M.-T. Dimanche-Boitrel, M. Samson and J. Le Seyec 699

The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis

I. Ilic and T. Milovanovic 701

Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy

A. Di Giorgio, E. Nicastro, C. Speziani, M. De Giorgio, L. Pasulo, B. Magro, S. Fagioli and L. D' Antiga 702

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

A.M. Moon, G.J. Webb, C. Aloman, M.J. Armstrong, T. Cargill, R. Dhanasekaran, J. Genescà, U.S. Gill, T.W. James, P.D. Jones, A. Marshall, G. Mells, P.V. Perumalswami, X. Qi, F. Su, N.N. Ufere, E. Barnes, A.S. Barritt IV and T. Marjot 705

A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities
M. Serper, A. Shaked, K.M. Olthoff, M. Hoteit, B. Appolo and K.R. Reddy 708

Lack of genetic evidence that fatty liver disease predisposes to COVID-19
L. Valenti, O. Jamialahmadi and S. Romeo 709

Clinical characteristics of COVID-19 patients with abnormal liver tests
P. Chen and B. Zhou 712

Reply to: "Clinical characteristics of COVID-19 patients with abnormal liver tests"
Q. Cai and J. Chen 713

Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents
S.H. Choi, S.Y. Kim and Y.-S. Lim 714

Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents"
A. Paisant, V. Vilgrain and C. Aubé 716

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease
L. Biquard, D. Valla and P.-E. Rautou 717

Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'
D. Ji, J. Xu, E. Qin, D. Zhang, G. Cheng, Y. Wang and G. Lau 718

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis
Y.-J. Zhou, K.I. Zheng, X.-B. Wang, H.-D. Yan, Q.-F. Sun, K.-H. Pan, T.-Y. Wang, H.-L. Ma, Y.-P. Chen, J. George and M.-H. Zheng 719

Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'
D. Ji, E. Qin and G. Lau 722

NAFLD or comorbidities, that is the question
F.R. Ponziani, A. Gasbarrini and M. Pompili 723

Reply to: 'NAFLD or comorbidities, that is the question'
D. Ji, D. Zhang and G. Lau 724

MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans
P.K. Luukkonen, A. Juuti, H. Sammalkorpi, A.K. Penttilä, M. Orešić, T. Hyötyläinen, J. Arola, M. Orho-Melander and H. Yki-Järvinen 725

Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data
B. Guiu 727

Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
M.J. Sonneveld, W.P. Brouwer and R.A. de Man 728

Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page"
H.L.-Y. Chan, V.W.-S. Wong, T.C.-F. Yip and G.L.-H. Wong 729

Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis
M.J.W. McPhail and M. Coen 730

Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis"
R. Moreau, F. Aguilar and V. Arroyo 732

Toxicity and dosimetry in SORAMIC study
M. Reinders, A. Braat and M. Lam 734

Reply to: "Toxicity and dosimetry in SORAMIC study"
J. Ricke, B. Sangro, P. Malfertheiner, M. Seidensticker and A. Todica 735

Transition of AKI to CKD in cirrhosis – effect of baseline eGFR and unanswered questions
I. Singh, A. De and V. Singh 737

Reply to: "Transition of AKI to CKD in cirrhosis – effect of baseline eGFR and unanswered questions"
O. Bassegoda, E. Solà and P. Ginès 738

ERRATA

Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25)
J. Ampuero, R. Aller, R. Gallego-Durán, J. Crespo, J.L. Calleja, C. García-Monzón, J. Gómez-Camarero, J. Caballería, O. Lo Iacono, L. Ibañez, J. García-Samaniego, A. Albillos, R. Francés, C. Fernández-Rodríguez, M. Diago, G. Soriano, R.J. Andrade, R. Latorre, F. Jorquera, R.M. Morillas, D. Escudero, P. Estévez, M. Hernandez-Guerra, S. Agustín, J. Bañales, P. Aspichueta, S. Benlloch, J.M. Rosales, J. Salmerón, J. Turnes and M. Romero-Gómez, on behalf of HEPAmet Registry 740

Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)"
X. Zhang, L. Fan, J. Wu, H. Xu, W.Y. Leung, K. Fu, J. Wu, K. Liu, K. Man, X. Yang, J. Han, J. Ren and J. Yu 742

CORRIGENDUM

Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]
M. Ruart, L. Chavarria, G. Campreciós, N. Suárez-Herrera, C. Montironi, S. Guixé-Muntet, J. Bosch, S.L. Friedman, J.C. Garcia-Pagán and V. Hernández-Gea 744

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: COVID-19: abnormal liver function tests, by Qingxian Cai *et al.* on pp. 566–574 in this issue.

Artwork: COVID-19 overshadows the liver function. Illustration by Luciana Giono.